Macrolide antibiotic binding to the ribosome inhibits catalysis of peptide bond formation between specific donor and acceptor substrates. Why particular reactions are problematic for the macrolide-bound ribosome remains unclear. Using comprehensive mutational analysis and biochemical experiments with synthetic substrate analogs, we find that the positive charge of these specific residues and the length of their side chains underlie inefficient peptide bond formation in the macrolide-bound ribosome. Even in the absence of antibiotic, peptide bond formation between these particular donors and acceptors is rather inefficient, suggesting that macrolides magnify a problem present for intrinsically difficult substrates. Our findings emphasize the existence of functional interactions between the nascent protein and the catalytic site of the ribosomal peptidyl transferase center.
In Brief
Macrolide antibiotics stall ribosomes at the Arg/Lys-X-Arg/Lys motif. Sothiselvam et al. find that the charge and size of key amino acid side chains in this motif make peptide bond formation inefficient. Antibiotics greatly magnify the problem of these intrinsically difficult donoracceptor pairs.
INTRODUCTION
The ribosome is an incredibly complex and sophisticated protein synthesis machine that represents one of the major antibiotic targets in bacterial cells (Wilson, 2009) . Although many ribosometargeting inhibitors completely abolish protein synthesis, some of them interfere with translation in a context-specific manner. Macrolides, such as erythromycin (ERY) and its derivatives, represent the best-studied examples of inhibitors whose action critically depends on the amino acid sequence of the synthesized protein (Davis et al., 2014; Hardesty et al., 1990; Kannan et al., 2012 Kannan et al., , 2014 Starosta et al., 2010) . Depending on the nature of the nascent chain and the structure of the drug, synthesis of the polypeptide can be arrested during very early rounds (Otaka and Kaji, 1975; Tenson et al., 2003) , at the later stages of translation elongation (Davis et al., 2014; Kannan et al., 2014) , or not at all (Kannan et al., 2012; Starosta et al., 2010) . Although optimizing clinical outcomes of antibiotic therapy hinges on achieving an understanding of the mode of drug action, a mechanistic explanation for the context specificity of macrolides is lacking.
Macrolide antibiotics target the large ribosomal subunit. The drugs bind in the nascent peptide exit tunnel (NPET) at a short distance from the peptidyl transferase center (PTC). Binding of the antibiotic obstructs the NPET and restricts placement of the nascent chain in the tunnel and its progression from the PTC to the tunnel exit (Bulkley et al., 2010; Dunkle et al., 2010; Schl€ unzen et al., 2001; Tu et al., 2005) . When the newly synthesized peptide chain grows to around four amino acids, it reaches the site of antibiotic binding (Arenz et al., 2014a (Arenz et al., , 2014b . Synthesis of some proteins by the drug-bound ribosome is interrupted at this stage, especially when the macrolide, like ERY, contains a C3-bound cladinose sugar that protrudes into the lumen of the tunnel (Bulkley et al., 2010; Dunkle et al., 2010; Schl€ unzen et al., 2001 ). However, some nascent peptides are able to bypass the antibiotic, allowing their continued synthesis in spite of the presence of a bulky drug molecule in the NPET (Hardesty et al., 1990; Kannan et al., 2012; Starosta et al., 2010) . Ketolide drugs, which lack a C3 cladinose, rarely inhibit translation at the early stages, and synthesis of many proteins continues past the initial rounds of protein elongation (Kannan et al., 2012 (Kannan et al., , 2014 .
Although macrolides do not inhibit synthesis of many proteins at the early rounds, translation of the majority of polypeptides by the drug-bound ribosome is eventually interrupted at the later stages of elongation (Davis et al., 2014; Kannan et al., 2014) . Strikingly, abrogation of translation does not occur randomly, but, rather, drug-bound ribosomes become arrested at specific, well defined mRNA sites. Ribosome profiling analysis carried out in Gram-positive and Gram-negative bacteria treated with macrolides helped identify the major sites of late translation arrest and allowed for initial classification of problematic sequences (Davis et al., 2014; Kannan et al., 2014) . Several amino acid motifs conducive to macrolide-induced arrest emerged from these studies. One of the most prevalent motifs conforms to the consensus R/K-X-R/K, where R and K represent arginine and lysine, respectively, and X represents any amino acid. In vitro biochemical testing supported the conclusion drawn from the profiling analysis that the ribosome stalls when the codon specifying the middle amino acid (X) of the motif enters the P site. Accordingly, the first residue of the consensus (R or K) represents the penultimate amino acid of the nascent peptide chain, whereas the last consensus sequence residue (also R or K) corresponds to the A site-bound aminoacyl-tRNA (Davis et al., 2014; Kannan et al., 2014; Sothiselvam et al., 2014) .
Importantly, the context specificity of antibiotic action is exploited for the regulation of expression of resistance genes (reviewed in Weisblum, 1995) . The inducible macrolide resistance genes remain silent in the absence of the antibiotic but are activated in its presence. Activation relies on programmed ribosome stalling at a precise, evolutionarily defined site of the regulatory upstream open reading frame (uORF) that precedes the resistance gene (Ramu et al., 2009; Subramanian et al., 2011; Weisblum, 1995) . The ribosomes arrested at the uORF alter the folding of the mRNA, activating the expression of the downstream resistance cistron. The structure of the antibiotic and the sequence of the leader peptide are the two main factors that determine the site of programmed translation arrest (Arenz et al., 2014a (Arenz et al., , 2014b Gryczan et al., 1980; Horinouchi and Weisblum, 1980; Ramu et al., 2011; Vá zquez-Laslop et al., 2008 . Strikingly, the R/K-X-R/K sequence, identified as one of the major motifs of macrolide-induced translation arrest (Davis et al., 2014; Kannan et al., 2014) , is present in many of the regulatory uORFs of macrolide resistance genes, including the wellstudied ermDL ORF that controls expression of the ermD gene (Kwak et al., 1991; Kwon et al., 2006; Sothiselvam et al., 2014) . In all tested regulatory uORFs with the R/K-X-R/K motif, the ribosome stalls when the second codon of the consensus enters the ribosomal P site (Almutairi et al., 2015; Sothiselvam et al., 2014) .
Strikingly, in the stalled ribosome, the amino acid residues of the R/K-X-R/K motif are located at the PTC active site rather than being juxtaposed next to the antibiotic molecule bound in the NPET (Arenz et al., 2014a (Arenz et al., , 2014b . Similarly, other stalling motifs identified in ribosome profiling experiments were also confined to the C-terminal residues of the nascent chain and the incoming amino acid (Davis et al., 2014; Kannan et al., 2014) . These observations led to the conclusion that, at least at the late elongation stage, macrolides do not hinder translation by simply barricading the NPET but, rather, act as context-specific PTC inhibitors (Kannan et al., 2014) . Indeed, RNA chemical probing showed that binding of macrolides to the NPET of the vacant ribosome was sufficient to allosterically induce structural changes in the PTC (Sothiselvam et al., 2014) . In agreement with this view, translation of the 5 0 terminally truncated ermDL ORF, which encodes the peptide starting with the MRLR sequence, was efficiently arrested by macrolides at the Leu3 codon, when the nascent chain was only three amino acids long and had only limited contacts with the drug. These results suggested that inhibition of translation elongation by macrolides does not necessarily require blocking the progression of the nascent chain in the drug-obstructed NPET but, rather, that binding of the antibiotic allosterically renders the PTC more restrictive toward its substrates, thus predisposing the ribosome for translation arrest when certain combinations of donors and acceptors meet at the catalytic center (Kannan et al., 2014; Sothiselvam et al., 2014) .
Despite the importance of understanding the precise molecular mechanisms of antibiotic action for the development of better drugs and for the exploration of ribosome functions, the basis for macrolide specificity remains obscure. It is poorly understood why certain combinations of donor and acceptor substrates, defined by the identified consensus sequences, are troublesome for the drug-bound ribosome. In particular, for the translation arrest directed by the R/K-X-R/K sequence, one could envision that either the positive charge or the extended length of the side chains of the arginine and lysine residues of the motif could be the dominant factor contributing to stalling. It is also unclear whether the binding of macrolide antibiotics to the ribosome causes some normally ''easy'' substrates to become ''difficult'' or whether the drugs simply exacerbate the challenging nature of intrinsically problematic substrates.
To gain further mechanistic insight into the mode of action of macrolide antibiotics, in this work we investigated the effect of the drug on the ability of the ribosome to catalyze the transfer of the short nascent MRL peptide to acceptor substrates that differ in their physicochemical properties. The lack of an extended nascent chain in this stalled complex allowed us to minimize the contribution of the context preceding the stalling motif on translation arrest (Davis et al., 2014; Elgamal et al., 2014; Kannan et al., 2014; Starosta et al., 2014; Woolstenhulme et al., 2013) . We found that two factors, the length of the side chains of the amino acid residues in the donor and acceptor substrates and, even more importantly, the positive charge of the critical residues, contribute to macrolide-induced arrest. Interestingly, our results indicate that the model substrates that react extremely slowly in the presence of antibiotic appear to be problematic donor-acceptor pairs even for the drug-free ribosome.
RESULTS
Antibiotic-Mediated Translation Arrest at the MRLR ORF Is Independent of the mRNA Sequence and tRNA Structure Our previous experiments showed that macrolide antibiotics arrest translation of the truncated ermDL gene (MRLR.) when the Leu3 codon is placed in the ribosomal P site and the Arg4 codon enters the decoding site (Sothiselvam et al., 2014) . To test whether macrolide-induced ribosome stalling is influenced by the structures of mRNA or tRNA, we changed codons 2-4 of the truncated ermDL template to several different combinations of synonymous triplets that not only alter the mRNA sequence but also direct binding of different aminoacyl-tRNA isoacceptors ( Figure S1A ). Toeprinting analysis showed that these alterations in mRNA sequence had minimal effects on the efficiency of ERYdirected arrest ( Figure S1A ). Therefore, neither the mRNA sequence nor the structure of the tRNA body affect macrolidedependent ribosome stalling at the truncated ermDL ORF, leaving the nature of the nascent peptide sequence as the likely primary determinant of translation arrest.
Only the Templates Encoding Arg or Lys in the Second and Fourth Codons Are Conducive to ERY-Induced Translation Arrest In the ribosome stalled at the truncated ermDL template, the MRL tripeptide esterifies the P site tRNA Leu , and the A site codon specifies for Arg-tRNA. We wanted to understand how the chemical nature of the peptidyl donor and aminoacyl acceptor affects catalysis of peptide bond formation by the drug-bound ribosome. First, we investigated the contributions of the second and third amino acids of the peptidyl moiety of the donor substrate, MRL-tRNA, to macrolide-dependent translation arrest. Codons 2 and 3 of the MRLR ORF, which encode the penultimate and the C-terminal residues of the nascent peptide, were mutated to specify all other 19 amino acids, and ERY-induced ribosome stalling in these templates was analyzed by toeprinting. Most of the alterations of the penultimate amino acid (Arg2) abolished stalling. Only the Arg2-to-Lys replacement maintained efficient translation arrest ( Figure 1A ). In contrast, the nature of the C-terminal residue was of much lesser importance. Only changes of Leu3 to Trp or Pro showed a somewhat increased bypass of the arrest site, whereas the majority of the mutants directed ribosome stalling as readily as the wild-type sequence ( Figure 1B) .
We then examined the role of the acceptor substrate. By mutating the fourth codon of the MRLR ORF, we directed binding of aminoacyl-tRNAs linked to each of the 20 different amino acids to the ribosomal A site. Similar to the effect observed for the penultimate position of the nascent peptide, only the Arg4-to-Lys (and, to a much lesser extent, the Arg4-to-Trp) substitution was conducive to ERY-induced stalling ( Figure 1C ). Thus, ERY promotes the formation of a stable stalled ribosome complex preferentially on those short templates where the second and fourth codons specify either Arg or Lys.
Because individual substitutions of Arg2 or Arg4 with Lys were compatible with ERY-induced stalling, we also tested whether simultaneous replacement of both Arg codons with Lys would still support translation arrest. Indeed, we found that the majority of the ribosomes that reached the third codon of the MKLK template became arrested ( Figure S1B , black arrowheads, lane L). In addition, similar to the results obtained with the MRLR template, mutations of the Leu3 codon, sandwiched between the two Lys codons in the MKLK template, had little effect on ERY-induced arrest ( Figure S1B ). An exception was the MKPK sequence. In this template, drug-bound ribosomes could not reach the third codon because they stalled at the Lys2 codon ( Figure S1B , lane P), likely because of the reported propensity of macrolides to inhibit peptide bond formation between a donor peptide with a C-terminal lysine and prolyl-tRNA (Davis et al., 2014; Kannan et al., 2014) .
Altogether, our mutational studies showed that the antibiotic bound in the ribosomal exit tunnel efficiently and specifically prevents the transfer of nascent tripeptides that have an Arg or Lys as their penultimate residues to an Arg or Lys acceptor ( Figure 1D ). , 2008) . In contrast, both cladinosecontaining macrolides as well as ketolides arrest translation of the truncated ErmDL (Sothiselvam et al., 2014) . We asked whether the identity of the second and fourth codons of the MRLR template, which is critical for ERY-induced arrest (Figure 1) , is also important for ribosome stalling directed by other macrolide antibiotics. Therefore, we tested the response of ErmDL mutants to the fluoroketolide solithromycin (SOL) and the cladinose-containing 15-member ring azithromycin (AZI) ( Figure S2A ). Similar to the effects observed with ERY, the mutation of Arg2 or Arg4 to Ala completely abolished arrest induced by SOL or AZI. Furthermore, similar to the effect on ERY-mediated arrest, altering the third codon (Leu) to Ala allowed for efficient arrest directed by AZI or SOL (although this mutation caused some read-through of the SOL-bound ribosome) ( Figure S2B ). We concluded that the nature of the penultimate residue of the short nascent peptide and the incoming amino acid are the most critical for arrest induced by a broad range of macrolide antibiotics.
Antibiotic Exacerbates the Difficulty of Peptide Bond Formation between Intrinsically Problematic Ribosomal Substrates
The results presented above strongly suggest that the ribosome with a macrolide antibiotic bound in the exit tunnel stalls when it needs to catalyze the transfer of tripeptides MRX or MKX to an Arg or Lys acceptor. To substantiate this conclusion, we followed the kinetics of peptide bond formation between the donor MRL-tRNA and different model acceptor substrates. For these experiments, we synthesized chemically stable substrates mimicking the aminoacyl-tRNA acceptor end (Graber et al., 2010; Moroder et al., 2009;  Table 1 ). In these aminoacyl-tRNA analogs with the general structure ACCA-X, various amino acid residues (X) were linked to the 3 0 carbon atom of the universal tRNA sequence ACCA via a stable amide bond (Supplemental Information). Binding of these substrates to the ribosomal A site does not require the elongation factor EF-Tu or interaction with the mRNA codon in the decoding center, and their acceptor ability depends exclusively on the nature of the amino acid residue. In the initial series of experiments, we used analogs that contained canonical amino acid residues that are either conducive to stalling (X = Arg or Lys) or abolish the arrest (X = Ala) ( Table 1) .
The ribosome/mRNA/MRL-tRNA complex was prepared by translating the MRL peptide from a synthetic tri-codon mRNA in the PURE cell-free translation system (Shimizu et al., 2001) . Because the mRNA lacks a stop codon, the ribosome stalls at the third codon carrying the tripeptidyl MRL-tRNA Leu bound in the P site and a vacant A site regardless of the presence of ERY (Figure 2A ). The stalled ribosome complexes were then mixed with high concentrations (0.7 mM) of the acceptor substrates, and the progression of the peptidyl transfer reaction was monitored by quantifying the amount of unreacted MRL-tRNA Leu resolved in Bis-Tris polyacrylamide gels ( Figure 2B ; Figure S3A ). Upon addition of the ACCA-NAla acceptor substrate, irrespective of the presence of ERY, the reaction was completed within 30 s (the shortest incubation time we could reliably measure with our experimental setup) (apparent rate constant k app > 1.8 min À1 ) (Figures 2B Table 1 ). This indicates that both the drug-free and ERY-bound ribosomes efficiently catalyze transfer of MRL to the non-stalling Ala acceptor. In striking contrast, in the presence of ERY, the majority of MRL-tRNA Leu remained unreacted with the ACCA-N-Arg or ACCA-N-Lys acceptors after 30 min of incubation ( Figures 2B and 2C) . Interestingly, although the absence of the antibiotic caused the reaction with these analogs to accelerate nearly 10-fold (k app = 0.9-1.5 min À1 ), it remained notably slower in comparison with the ACCA-N-Ala substrate (Figures S3A and S3B ; Table 1 ). The marked reduction in the reaction rate between MRL-tRNA and ACCA-N-Arg or ACCA-N-Lys acceptors in the absence of antibiotics was not manifested in the conventional toeprinting experiments (no-antibiotic lanes, Figures 1A-1C) , likely because the putative ribosome pausing was too transient to be captured by this assay. Nevertheless, the results of biochemical testing clearly show that the transfer of the MRL donor to the Arg or Lys acceptors is intrinsically difficult for the ribosome and that the presence of the antibiotic in the exit tunnel dramatically intensifies the problem, essentially halting peptide bond formation. See also Figure S3 .
The Positive Charge of the A Site Substrates Is the Predominant Factor that Makes Them Poor Acceptors of the MRL Peptide Arg and Lys are unique among the 20 canonical amino acids because they contain the longest side chains, which are positively charged at physiological pH. We considered that the size, the charge, or the combination of these two features could make it difficult for the ribosome to use Arg-tRNA or Lys-tRNA as acceptors of the MRL peptide, hence leading to translation arrest. To dissect the contribution of length and charge of the acceptor's side chain to antibiotic-mediated ribosome stalling, we prepared a new series of synthetic substrate analogs that varied in the length of the side chain and in the presence or absence of the positive charge (Table 1) . We then tested the acceptor activity of these substrates in the same experimental setup we used before with the Ala, Lys, or Arg acceptor analogs. In the presence of ERY, the transfer of the MRL peptide to ACCA-N-6-azido-L-norleucine, ACCA-N-6-hydroxy-L-norleucine, or ACCA-N-6-ethyl-L-norleucine, whose side chain skeletons range in length from five to seven non-hydrogen atoms but lack the net positive charge, occurs with the apparent rate constant k app of $0.3 min À1 (Figure 3 ; Table 1 ). Remarkably, shortening the uncharged side chain to four carbon atoms (in ACCA-N-norleucine) significantly accelerated the reaction, making it too fast to accurately determine the rate constant in our experiments (k app > 1.8 min À1 ) (Figure 3 ; Table 1 ). Likewise, in the absence of the antibiotic, all uncharged acceptor substrates reacted with kinetics too rapid to be accurately measured (Figure S3B ; Table 1 ). These results showed that the length of the acceptor side chain contributes to the arrest mechanism because macrolides notably slow down the transfer of the MRL peptide with acceptors having extended side chains. Nevertheless, the reaction of the MRL peptide with electroneutral acceptors still proceeded at a considerable rate, indicating that the extended length of the acceptor side chain is insufficient to support formation of a stable stalled complex.
Introduction of the positive charge to the side chain on the acceptor substrate exhibited a more dramatic effect on the rate of reaction with the MRL donor. Replacement of the terminal methyl group of norleucine with a positively charged amino group in ACCA-N-ornithine resulted in a precipitous drop of the MRL transfer rate, essentially abolishing the reaction in the presence of ERY (k app < 0.01 min À1 ) (Figure 3 ; Table 1 ). In addition, consistent with what was observed for Arg and Lys acceptors, even in the absence of ERY, the transfer of the MRL peptide to ACCA-N-ornithine was rather inefficient (k app = 0.08 ± 0.02 min À1 ) (Figure S3B ; Table 1 ). These results clearly indicate that the major obstacle for catalysis of the transfer of the MRL peptide to the acceptor in the PTC of the macrolide-bound ribosome is imposed by the charge of the A site amino acid. However, in agreement with the notion of the importance of the size of the side chain, ACCA-N-aminoalanine, with a positively charged side chain as short as two non-hydrogen atoms, reacted faster than any of the other tested positively charged acceptors (k app = 0.61 ± 0.16 min À1 ) ( Figure 3 ; Table 1 ) but much slower than any of the uncharged substrates with a side chain shorter than five atoms.
The sluggish transfer of the MRL peptide to the positively charged substrates ACCA-N-Lys, ACCA-N-Arg, and ACCA-Nornithine critically depends on the presence of Arg (or Lys) in the penultimate position of the nascent chain. The non-stalling donor peptide MAL swiftly reacted with the acceptor substrates containing Ala, Lys, or Arg residues irrespective of the presence of antibiotic (k app R 0.74 min À1 ) (Figures 2D-2F ; Figures S3C and S3D; Table 1 ). Consequently, removal of the long, positively charged side chain of the penultimate residue of the donor substrate allows for efficient peptidyl transfer even to positively charged A site substrates. Thus, it appears that the simultaneous presence of the charged long side chains in the penultimate position of the donor substrate and in the aminoacyl acceptor present the obstacle for catalysis of peptide bond formation by the macrolide-bound ribosome.
One possible model that follows from our findings is that a simple electrostatic repulsion between the penultimate residue of the peptidyl donor and the aminoacyl moiety of the acceptor may be sufficient to hamper the catalysis of the peptidyl transfer reaction in the macrolide-bound ribosome. If this were the case, then simultaneous replacement of the positively charged residues encoded in codons 2 and 4 of the MRLR ORF with negatively charged amino acids would be comparably detrimental for translation. We tested this hypothesis in a straightforward toeprinting experiment exploiting two new templates in which the second and the fourth codons of the MRLR ORF were mutated to specify peptides MDLD and MELE, which carry negatively charged amino acids in the critical positions (Figure 4) . However, neither of these peptides were able to direct efficient arrest of the macrolide-bound ribosome. Thus, it is not the simple repulsion of two equivalent charges but the explicit presence of positive charges at the extended side chains of the penultimate residue of the P site peptidyl donor and of the A site aminoacyl acceptor that obstructs peptide bond formation in the ribosome with a macrolide antibiotic bound in the NPET.
DISCUSSION
In our experiments, we interrogated one of the most common problematic motifs for the macrolide-bound ribosome, R/K-X-R/K, and found that specific physicochemical properties of substrates participating in peptide bond formation are the major contributing factors to drug-induced translation arrest. During translation elongation, macrolides act as inhibitors of peptide bond formation between specific combinations of PTC donor and acceptor substrates (Kannan et al., 2014) . This mode of action is possibly mediated by allosteric changes in the PTC induced by the drug (Sothiselvam et al., 2014) . In addition, direct interactions between the nascent chain and the antibiotic in the NPET may also modulate antibiotic action (Arenz et al., 2014a (Arenz et al., , 2014b Vá zquez-Laslop et al., 2010) and may at times allow the drug-bound ribosome to bypass a problematic motif (S.S., unpublished data). Such influence of the context likely explains why, in macrolide-treated cells, no significant increase in ribosome density is observed at some of the R/K-X-R/K sequences (Davis et al., 2014; Kannan et al., 2014) . Our use of the shortest known peptide capable of directing macrolide-dependent ribosome stalling, MRL (Sothiselvam et al., 2014) , allowed us to significantly simplify the system by minimizing the influence of the N-terminal context on the druginduced arrest. Furthermore, the small size of the stalling peptide made it possible to probe the contribution of each of its residues (with the exception of the N-terminal formyl-methionine) to translation arrest.
Strikingly, in the context of the short donor substrate, the physicochemical characteristics of only one of its residues, the penultimate amino acid, are critical. The properties of the C-terminal amino acid, which directly participates in peptide bond formation, are of lesser importance. Our comprehensive mutational analysis showed that the simultaneous presence of Lys or Arg residues in the penultimate position of the peptide and in the acceptor substrate is sufficient for preventing fast peptide bond formation in the macrolide-bound ribosome. Subsequent biochemical studies that utilized different peptidyl donors (MRL and MAL) and a series of synthetic acceptors showed that the positive charge of the critical amino acid residues and the size of their side chains are the key factors that render peptide bond formation inefficient in the drug-bound ribosome. The positively charged, long side chain acceptors of the MRL peptide (ACCA-N-Arg, -Lys, or -ornithine) reacted extremely slowly, whereas shortening of the positively charged side chain (ACCA-N-aminoalanine) or removal of the charge increased the reaction rate, with the most dramatic acceleration achieved with short uncharged acceptor substrates (Figure 3) . Importantly, substituting the electroneutral Ala for Arg in the penultimate position of the donor (MAL) had a similar effect.
Although the contribution of the size of the side chain in natural substrate analogs could be generally concealed because of the dominance of the charge effect, it might nevertheless play a role in the effects of the drugs on cellular translation. Indeed, although, in our in vitro experiments, both ACCA-N-Lys and ACCA-N-Arg reacted too slowly to accurately distinguish the difference in their reactivity, ribosome profiling analysis showed a more pronounced enrichment of Arg-containing sequences of the R/K-X-R/K motif in the sites of macrolide-induced translation stalling (Davis et al., 2014; Kannan et al., 2014) . Because the guanidinium group of Arg and the ε-amino group of Lys are both completely protonated at physiological pH, it is generally possible that the longer side chain of Arg (six atoms) compared with Lys (five atoms) accounts for a more severe translation arrest at the Arg-containing motifs.
Our findings provide an explanation for a long-known fact: that translation of poly(A) RNA, encoding poly-lysine, is efficiently inhibited by erythromycin and results in accumulation of short (dito penta-lysine) peptides (Mao and Robishaw, 1971; Otaka and Kaji, 1975; Vazquez, 1966) . Because the poly(Lys) sequence conforms to the R/K-X-R/K motif, it is not surprising that its Toeprinting analysis of ERY-dependent ribosome stalling at the templates encoding MDLD and MELE peptides. The full sequences of the WT and mutant ermDL ORF and the encoded peptides are shown above the gel. The penultimate (À1) amino acid residue of the nascent chain in the drug-stalled ribosome, the P site, and the A site residues are marked above the peptide sequence. Black arrows indicate ERY-dependent translation arrest at the Leu codon. Gray arrows indicate the toeprint bands representing ribosomes captured at the downstream Pro5 codon because of the presence of mupirocin in the reaction mixture, which inhibits the Ile-tRNA formation. Sequencing lanes are marked. The shown gel is representative of two independent experiments. synthesis would be interrupted by macrolides at the very early rounds because the drugs should block the transfer of even very short nascent chains carrying Lys in the penultimate position to the incoming Lys-tRNA.
Our results show that the interplay of the penultimate residue of the nascent peptide and the incoming amino acid has a dramatic effect on macrolide-induced arrest at the R/K-X-R/K sites. The nature of the C-terminal residue of the donor peptide that resides in the PTC P site appears to be far less significant, at least in the case of ERY-induced arrest with the minimal peptide (Figure 1B) . Nevertheless, from the somewhat varying relative intensity of the arrest bands in the toeprint gels ( Figure 1B) , it could be inferred that the C-terminal residue does modulate, to some extent, the efficiency of peptide bond formation in the macrolide-bound ribosome. The influence of the C-terminal peptide residue could account for the varying extent of enrichment of different R/K-X-R/K sequences at the sites of ERY-induced arrest observed in ribosome profiling experiments (Kannan et al., 2014) . Furthermore, the nature of the tunnel-bound antibiotic affects the importance of the C-terminal residue of the nascent chain for translation arrest. Although Leu3-to-Ala replacement had only a negligible effect on the transfer of the MRL peptide to Arg-tRNA in the ERY-or AZI-bound ribosome, the same mutation notably diminished translation arrest when the fluoroketolide SOL was bound ( Figure S2 ). This result is reminiscent of our recent finding that the nature of the C-terminal residue of another stalling regulatory peptide, ErmBL, which conforms to a different stalling motif, XDK (Kannan et al., 2014) , determines whether macrolides or ketolides are recognized as the stalling cofactor (Gupta et al., 2016) .
Several scenarios could account for the slow transfer of a peptidyl donor with a positively charged penultimate residue to a positively charged acceptor in the ERY-bound ribosome. One possibility is that electrostatic repulsion between the incoming amino acid and the penultimate nascent peptide residue, possibly exacerbated by direct steric hindrance and a close proximity of the charges located at the ends of the extended side chains, prevents proper accommodation of the aminoacyl-tRNA acceptor in the PTC A site (Arenz et al., 2014a (Arenz et al., , 2014b Gupta et al., 2016; Ramu et al., 2011) . This could lead to either an aberrant placement of the stably bound aminoacyl-tRNA or to rapid dissociation of Arg-or Lys-tRNA from the A site. It is also possible that binding of the positively charged substrate to the A site displaces the peptidyl-tRNA in the P site when its penultimate position is occupied by a positively charged residue. Finally, both the donor and acceptor substrates could be mutually misaligned in the PTC active site, which would be detrimental for efficient peptide bond formation.
Although the charge of the amino acids in the donor and acceptor substrates plays the key role in macrolide-induced arrest, only positively charged residues were detrimental for peptide bond formation. Simultaneous replacement of both of the critical residues with negatively charged amino acids was not conducive to translation arrest (Figure 4) . It is thus obvious that the polarity of the charge of the donor and acceptor is central to the mechanism of stalling. In agreement with this conclusion, although R/K-X-R/K is one of the most predominant macrolide stalling motifs in Gram-positive and Gram-negative bacteria (Davis et al., 2014; Kannan et al., 2014) , no particular enrichment of the D/E-X-D/E sequences at the sites of druginduced translation arrest has been noted. The strict polarity requirement suggests that electrostatic interactions of the substrates with additional charged group(s) in the ribosome or its ligands could be involved in the mechanism of stalling. It is conceivable that the positive charge at the end of the extended side chain of the (À1) residue of the peptidyl donor or aminoacyl acceptor could interact with the electronegative phosphate group of one of the neighboring 23S rRNA nucleotides. The generally electronegative potential of the NPET could be also a contributing factor (Lu et al., 2007) . Alternatively, the protonated 3 0 dimethyl-amino group of the macrolide molecule could influence the placement of the positively charged substrates in spite of the $8-Å distance that separates it from the PTC active site.
The rate of the catalytic step of peptide bond formation in the drug-free ribosome depends on the nature of the reacting substrates (Bourd et al., 1982; Johansson et al., 2011; Monro et al., 1968; Muto and Ito, 2008; Wohlgemuth et al., 2008) . However, this difference in reactivity is normally masked by the slow rate of aminoacyl-tRNA binding and accommodation, which is the rate-limiting step of translation elongation (Wintermeyer et al., 2004) . It is conceivable, however, that, if the general catalytic capacity of the PTC is decreased, then formation of peptide bonds between certain generally sluggish substrates could slow down sufficiently to become rate-limiting. From this standpoint, it is remarkable that, even in the absence of antibiotic, the reaction of the MRL peptide with the acceptor analogs carrying positively charged amino acids with extended side chains was notably slower that the reaction with electroneutral acceptors (Table 1 ). This observation hints that peptide bond formation between substrates conforming to the R/K-X-R/K motif is intrinsically slow. Therefore, macrolide antibiotics do not convert well behaved substrates into slow reactants. Rather, the drugs amplify the problem of the substrates that are inherently difficult, making peptide bond formation rate-limiting. We are fully aware, however, that the use of the artificial acceptor substrates may significantly aggravate the difference in their reactivity (Brunelle et al., 2006; Katunin et al., 2002) . Furthermore, the kinetic parameters obtained in the cell-free setting with the use of model substrates reflect only the general trend in relative substrate reactivity rather than the actual kinetics of transpeptidation, which should be much faster when the full-length tRNA delivers the acceptor amino acid to the PTC A site (Wohlgemuth et al., 2008) . Indeed, the lack of pronounced ribosome stalling at the R/K-X-R/K motif in the absence of antibiotic (Davis et al., 2014; Kannan et al., 2014; Li et al., 2012; Mohammad et al., 2016) suggests that, even for these slow substrates, the rate of transpeptidation in the living cell is not rate-limiting. Therefore, it is possible that inhibition of translation by macrolide antibiotics reveals a general but concealed phenomenon of the dependence of the rate of peptidyl transfer on the interplay of the penultimate residue of the nascent chain and the incoming amino acid.
Other sequence motifs conducive to macrolide action that do not conform to the R/K-X-R/K consensus are also confined to amino acid residues residing at or near the PTC. The features of those substrates that make them difficult for the drug-bound ribosome are currently unknown. Interestingly, however, one of the identified macrolide motifs (XPX) (Davis et al., 2014; Kannan et al., 2014) includes proline, a particularly slow participant in peptide bond formation (Johansson et al., 2011) , especially in specific contexts (Doerfel et al., 2013; Ude et al., 2013) . Therefore, our conclusion that macrolides exacerbate the problematic nature of the inherently difficult sequences could expand beyond the specific example of the R/K-X-R/K motif explored in this paper. Further exploration of the context specificity of macrolide action might reveal new hidden features of the general mechanisms of protein synthesis.
EXPERIMENTAL PROCEDURES Reagents
Erythromycin, azithromycin, and mupirocin were from Sigma-Aldrich, solithromycin was provided by Dr. Fernandes (CEMPRA Pharmaceuticals), and indolmycin was from Santa Cruz Biotechnology. The reverse transcriptase used in the toeprinting analysis was purchased from Sigma-Aldrich. All DNA primers (listed in Table S1 ) were synthesized by IDT.
The synthesis of ACCA-N-X substrates is described in the Supplemental Experimental Procedures.
Toeprinting Assay
Linear DNA templates (0.5-1 pmol) encoding the ORF of interest preceded by the T7 promoter sequence were generated by PCR using the primers indicated in Table S1 . To capture the ribosomes that escaped ERY-dependent arrest at the RLR sequence, an Ile codon (Ile6) was introduced after the Pro5 codon, and all reactions were carried out in the presence of 50 mM mupirocin, an IleRS inhibitor. In the templates where the codons of the motif were mutated to specify Ile, the Ile6 codon was replaced with a Trp codon, and, in these cases, reactions were carried out in the presence of indolmycin, an inhibitor of TrpRS.
Templates were used to direct coupled transcription-translation in the PURExpress cell-free system (New England Biolabs). The reactions were performed in a total volume of 5 ml and, where indicated, were supplemented with antibiotics (50 mM final concentration). Following 10-min incubation at 37 C, the primer extension reaction was initiated by addition of the primer NV1 (Table  S1 ) and 3 U of reverse transcriptase. The resulting cDNA products, along with sequencing reactions, were separated in a 6% sequencing gel and visualized with a Typhoon imager (GE Healthcare).
In Vitro Peptidyl Transfer Reaction Synthetic mRNAs (synthesized by Thermo Fisher) encoding MRL peptide (ATAAGGAGGAAAAAATATGAGACUU, the coding sequence is underlined) or MAL peptide (ATAAGGAGGAAAAAATATGGCACUU) were used for in vitro translation in the PURE system. The 5-ml reactions containing 75 pmol of the mRNA template were supplemented with 1 mCi [ 35 S]-methionine (specific activity, 1,175 Ci/mmol) and, where indicated, 50 mM ERY. Following 7-min incubation at 37 C, thiostrepton was added to the final concentration of 50 mM to prevent further rounds of translation. The synthetic acceptor substrate ACCA-N-X, dissolved in water, was then added to a final concentration of 0.7 mM. Aliquots (5 ml) were withdrawn at different times and immediately mixed with an equal volume of SDS-containing tricine sample buffer (BioRad). Reaction products were resolved in 16% Bis-Tris polyacrylamide gel as described previously (Vá zquez-Laslop et al., 2008) . Gels were fixed, dried, exposed to a phosphorimaging screen, and visualized with a Typhoon imager (GE Healthcare).
Quantification of the peptidyl-tRNA bands was performed using ImageJ (Schneider et al., 2012) . Because the reactions contain excess of [
35 S]-methionine and fMet-tRNA Met is continuously regenerated in the reaction, the fMettRNA Met band served as the loading control and normalization factor. The normalized peptidyl-tRNA band at t = 0, which represents the total amount of unreacted peptidyl-tRNA before addition of the A site substrates, was set at 100%. The progress of the reaction was monitored by quantifying the amount of unreacted peptidyl-tRNA at experimental time points. The data were fitted to one phase exponential decay model in GraphPad PRISM using the equation
where Y is the amount of unreacted peptidyl-tRNA (percent) at any given time point, Y0 is the initial amount of unreacted peptidyl-tRNA at t = 0, PL (plateau) is the Y value at infinite times (calculated in PRISM), k is the rate constant, and X is the time in minutes. The error range of the apparent rate constants shown in Table 1 
